Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.78B P/E - EPS this Y 31.70% Ern Qtrly Grth -
Income -440.22M Forward P/E -4.75 EPS next Y 44.20% 50D Avg Chg -9.00%
Sales 32.77M PEG 0.38 EPS past 5Y - 200D Avg Chg -1.00%
Dividend N/A Price/Book 2.42 EPS next 5Y -19.00% 52W High Chg -46.00%
Recommedations 1.90 Quick Ratio 4.74 Shares Outstanding 303.51M 52W Low Chg 36.00%
Insider Own 0.53% ROA -33.35% Shares Float 224.41M Beta 0.63
Inst Own 87.46% ROE -65.36% Shares Shorted/Prior 60.29M/59.33M Price 7.18
Gross Margin -44.43% Profit Margin - Avg. Volume 6,016,856 Target Price 24.42
Oper. Margin -327.64% Earnings Date Oct 30 Volume 4,421,887 Change -0.14%
About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics, Inc. News
10/12/24 Is Iovance Biotherapeutics, Inc. (IOVA) the Best Growth Stock Under $10 to Buy?
10/10/24 Is Iovance Biotherapeutics, Inc. (IOVA) the Best Stock Under $10 With High Potential?
10/09/24 Strong Investor Sentiment: Artisan Partners Highlights Iovance Biotherapeutics, Inc. (IOVA)
10/04/24 Is Iovance Biotherapeutics Stock a Buy?
10/03/24 High Growth Tech Stocks to Watch in October 2024
09/26/24 3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
09/16/24 Iovance Biotherapeutics (NASDAQ:IOVA) delivers shareholders favorable 74% return over 1 year, surging 4.9% in the last week alone
09/16/24 3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
04:32 PM Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock
09/12/24 Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
09/06/24 This Is the Biggest Risk With Iovance Biotherapeutics Stock
09/03/24 Iovance Biotherapeutics to Present at Upcoming Conferences
09/02/24 3 Monster Biotech Stocks to Buy Before 2025
08/27/24 Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
08/26/24 High Growth Tech Stocks To Watch In August 2024
08/16/24 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
06:15 AM This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
08/13/24 Industry Analysts Just Made A Sizeable Upgrade To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Revenue Forecasts
08/12/24 3 US Growth Companies With High Insider Ownership Growing Earnings Up To 68%
08/10/24 Iovance Biotherapeutics Second Quarter 2024 Earnings: Beats Expectations
IOVA Chatroom

User Image Badgerkid Posted - 38 minutes ago

$IOVA Here's a little takeaway from Stifel's recent Iovance report (pg. 9) discussing near term patient numbers and future patient expectations - the future numbers should truly impress you: "In our model, we estimate 2-3 patients per month at Top-Tier ATCs (N=10) and ~1-2 patients/month at non-Top-Tier ATCs over the short term. The exception here is 4Q24 – we model a slowdown in an effort to meet 2024 guidance, which would be consistent with moving past an initial patient bolus. Long term, we assume 8 patients per month at Top-Tier ATCs and 4/month at non-Top-Tier ATCs." Using 50 ATC's, that's conservatively 180 patients per Q near term. Their future expectation using 70 ATC's is conservatively over 900 patients per quarter. Do the math, that's nearly $2 billion in revenue for Amtagvi alone. Now consider what will happen when you add in additional indications for TIL - nsclc, endometrial, and others. Fair value for Iovance? Sell or don't sell the company, it's still a big number.

User Image zero1234 Posted - 1 hour ago

$IOVA slow and steady...

User Image Lolichocho Posted - 1 hour ago

$IOVA 65M revenue and raised 2025 guidance.

User Image Idvst8 Posted - 1 hour ago

$IOVA

User Image Idvst8 Posted - 1 hour ago

$IOVA

User Image Idvst8 Posted - 1 hour ago

$IOVA -6th Annual TIL Therapies Summit October 22-24, 2024 | Boston, MA

User Image thebullofwallst Posted - 2 hours ago

$IOVA The TIL Therapies Summit would be an ideal place for an interim NSCLC readout

User Image Milanfinest Posted - 2 hours ago

$IOVA hello what s the story here? I see is lateralizing and i m gonna read all the stories on various forum, but if the bio cowboys wanna share a recap many thanks!✈️🍝

User Image Bamin Posted - 3 hours ago

$IOVA Stifel Survey: Not sure what they mean by: "one respondent who indicated infusing 5 patients, 3 of which were OOS, and he said 2(of 3) were due to insufficient yield"?? Why would any patient be infused if the TIL product was "out of spec" unless they are giving the patient the benefit of the doubt and still infusing BUT IOVA would not be able to bill for such patients?

User Image Idvst8 Posted - 3 hours ago

$IOVA - The formal note below estimates Rev at $54mm, so that is Technically the Bar. To Crush.

User Image Idvst8 Posted - 3 hours ago

$IOVA - over/under Rev number for Q3 ER ?? I'm running with $60mm, and Hoping for a high Mark of $66mm. Big 10% beat

User Image tedevan Posted - 3 hours ago

@Chartist0_0 it's sector wide look at $iova and $espr both doing well and also facing massive shorts.

User Image NotHalfFast Posted - 4 hours ago

$IOVA here it is lads.

User Image Itsf82 Posted - 5 hours ago

$IOVA Green .. but expected better tbh

User Image Quadman5 Posted - 5 hours ago

$IOVA This just up on Webull news feed.

User Image CrypoCuzz Posted - 6 hours ago

$IOVA dip before the rip….i could only wish

User Image StockednLoaded Posted - 6 hours ago

$IOVA- LBPH acquired for 2.6B. Peak sales 1.5B-2B. Anticipates drug on market in 4yrs. addt’l ~4 yrs to hit peak sales? So 2.6B PV at ~3.5% 8 yrs = ~3.5B future value, but since it’s only a ph2 there needs to be some kind of discount to account for risk. I have no clue on discounts, but would a 75% probability be close to the best a Bio would expect on an offer that still carries huge risk towards its FV? ~3.5B FV discounted by ~25% puts the derisked value of the drug ~4.5B. Fred said amtagvi represents more than 1B opportunity for current label in US alone, if we assume LBPH and Amtagvi do similar sales 1.5-2B at similar margins and assume peak sales in ~3 more years off 4.5B that puts PV of current label ~4B. Mgmt also said they view EU market as equal to US. So another ~4B. De-risked stock price *today* should be $25-$30 before you even factor other markets + label expansion on 1L/NSCLC/addt’l pipeline. I know, I know retail was early and mgmt had to use ATM at $8. Makes sense 🤮

User Image Gettingtillywithit Posted - 6 hours ago

$IOVA the joke is on them sit tight

User Image SwordfishTrader Posted - 7 hours ago

$IOVA Guys this is a stereotypical accumulation pattern and method over recent months. It’s of 100% certainty this is the major load zone and we’re only dipping regularly for funds to accumulate more. Zero fear and buy all you can since that’s what the big money is doing every week we remain at these incredible bargain prices.

User Image Gramma Posted - 7 hours ago

$IOVA Sometimes people cant envision the future,In the early 90s went into a store,They were selling computers and electronics,Asked the old guy at the counter if i should buy a computer(they were expensive then) He said dont bother it will never catch on,Its only for nosey people,I said wrap it up ,I will take it!! Iova will catch on justs needs time.

User Image Gettingtillywithit Posted - 8 hours ago

$IOVA $10

User Image Idvst8 Posted - 8 hours ago

$IOVA Wakey wakey !!

User Image RumRunna Posted - 8 hours ago

$IOVA 💪🏼

User Image Gettingtillywithit Posted - 8 hours ago

$IOVA NEW HOD!!

User Image Gettingtillywithit Posted - 8 hours ago

$IOVA quit hiding $10!!!

User Image Gettingtillywithit Posted - 8 hours ago

$IOVA ALLEZ!!!!

User Image Gettingtillywithit Posted - 8 hours ago

$IOVA NEW HOD!!

User Image Badgerkid Posted - 8 hours ago

$IOVA FWIW, I just keep buzzing the tower and buying shares below $10. Found some spare change in the couch and added a few more shares. I might forgo that high end IPA at bowling so that I can buy a few more IOVA shares. Good luck to the longs.

User Image RexColbrook Posted - 9 hours ago

$IOVA ⏳🎶 lfg! 😎

User Image Badgerkid Posted - 9 hours ago

$IOVA FWIW, and as recently posted, hiring remains brisk, including some overlap on Iovance's site for WuXi staffing: https://www.iovance.com/current-opportunities/

Analyst Ratings
HC Wainwright & Co. Buy Aug 12, 24
Piper Sandler Neutral Jul 29, 24
HC Wainwright & Co. Buy Jun 28, 24
JMP Securities Market Outperform Jun 20, 24
HC Wainwright & Co. Buy Jun 3, 24
HC Wainwright & Co. Buy May 31, 24
HC Wainwright & Co. Buy May 24, 24
HC Wainwright & Co. Buy May 10, 24
Piper Sandler Overweight Mar 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Rothbaum Wayne P. Director Director Sep 15 Buy 5.3 5,000,000 26,500,000 23,067,333 09/15/23
Rothbaum Wayne P. Director Director Dec 02 Buy 6.50 10,000,000 65,000,000 18,067,333 12/02/22
Vogt Frederick G Interim CEO & Genera.. Interim CEO & General Counsel Nov 28 Buy 5.98 1,000 5,980 2,000 11/28/22
MCPEAK MERRILL A Director Director Nov 28 Buy 6.18 10,000 61,800 228,633 11/28/22
Dukes Iain D. Director Director Nov 23 Buy 6.10 10,000 61,000 22,000 11/28/22
MCPEAK MERRILL A Director Director May 31 Buy 6.82 20,000 136,400 218,633 06/02/22
Maynard Ryan D Director Director May 31 Buy 6.745 7,500 50,588 7,500 06/02/22
WEISER MICHAEL Director Director May 31 Buy 6.8 10,000 68,000 112,632 06/02/22
Vogt Frederick G Interim CEO & Genera.. Interim CEO & General Counsel Jun 01 Buy 6.44 1,000 6,440 1,000 06/02/22
Rothbaum Wayne P. Director Director May 31 Buy 6.6 1,000,000 6,600,000 8,067,333 06/02/22